Fig. 5.

SRI-4 responders by baseline disease severity on the basis of SLEDAI-2K (a), CLASI-Activity (b), and BILAG-2004 (c) scores in the mITT population *p < 0.05; **p < 0.01 from CMH test stratified for location (US and outside the US) and baseline glucocorticoid dose (≤ 20 and > 20 mg per day). BILAG-2004 British Isles Lupus Assessment Group-2004, CLASI-Activity Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity, CMH Cochran–Mantel–Haenszel, mITT modified intention-to-treat, OR odds ratio, PBO placebo, RCI repository corticotropin injection, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index-2000, SRI-4 Systemic Lupus Erythematosus Responder Index-4